Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Neurological Sciences
Erschienen in:

11.09.2024 | Original Article

Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness

verfasst von: Berenice A. Silva, Alejandra Heriz, Jeremías Ayerbe, Luciana Lázaro, Magdalena Casas, Pablo López, Verónica Tkachuk, María Eugenia Balbuena, Débora Nadur, Susana Liwacki, Geraldine Luetic, Marcos Burgos, Federico Casales, Agustina Piedrabuena, Edgar Carnero Contentti, Agustina Zárate, Gisela Zanga, Judith Steinberg, Carolina Mainella, Darío Tavolini, Javier Hryb, Felisa Leguizamón, Fátima Pagani Cassará, Gustavo José, Paula Carrizo, Pedro Nofal, Belén Luis, Cecilia Pita, Jimena Míguez, Ricardo Alonso

Erschienen in: Neurological Sciences | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy therapies options has been increasing along the years. Objective: to analyze the cladribine use trend across time since its approval.

Method

A retrospective cohort study was performed. People with MS (pwMS) treated with cladribine were included. Two periods were defined: P1 = 2018 – 2020 and P2 = 2021 – 2023. A comparative analysis was carry out between P1 and P2 to assess the trend of use, clinical/demographic characteristics, and effectiveness.

Results

One hundred ninety- seven people with MS (pwMS) were included, mean EDSS: 2.2 ± 3.08, 72.6% female, mean age: 35.2 ± 9 years, mean disease duration: 6.6 ± 5.6 years, mean time lapse under cladribine: 26.1 ± 12.4 months. Regarding patient profile, we found significant differences between P1 and P2 in the MS evolution (p = 0.001) and EDSS ( p = 0.018) prior to initiation of cladribine. In the individualized analysis by year, we found a decrease in relapse number in the year prior to starting cladribine (p = 0.02). A higher proportion of No Evidence of Disease Activity (NEDA) was found in patients treated at P2 compared to those treated at P1 (p < 0.001).

Conclusion

An earlier use of cladribine achieved a significant increase in reaching NEDA. This learning curve in the use of cladribine allows a better identification of the candidate patient and influences the treatment effectiveness.
Literatur
1.
2.
Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72(2):152–158CrossRefPubMed
3.
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S (2016) Optimizing treatment success in multiple sclerosis. J Neurol 263(6):1053–1065CrossRefPubMed
4.
Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H (2020) Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 16(1):56–62CrossRefPubMed
5.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, C.S. Group (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362(5):416–26CrossRefPubMed
6.
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P (2018) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 24(12):1594–1604CrossRefPubMed
7.
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, Rojas JI, Pappolla A, Patrucco L, Cristiano E, Burgos M, Vrech C, Piedrabuena R, Pablo L, Deri N, Luetic G, Miguez J, Cabrera M, Martinez A, Zanga G, Tkachuk V, Tizio S, Carnero Contentti E, Knorre E, Leguizamon F, Mainella C, Nofal P, Liwacki S, Hryb J, Menichini M, Pestchanker C, Alonso M, Garcea O, Silva B (2023) Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. Mult Scler J Exp Transl Clin 9(1):20552173231154710PubMedPubMedCentral
8.
Alonso R, Casas M, Lazaro L, Liguori NF, Pita C, Cohen L, Rojas JI, Pappolla A, Patrucco L, Cristiano E, Burgos M, Vrech C, Piedrabuena R, Pablo L, Deri N, Luetic G, Miguez J, Cabrera M, Martinez A, Zanga G, Tkachuk V, Tizio S, Carnero Contentti E, Knorre E, Leguizamon F, Mainella C, Nofal P, Liwacki S, Hryb J, Menichini M, Pestchanker C, Garcea O, Silva B (2023) Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina. Mult Scler Relat Disord 79:104935CrossRefPubMed
9.
Giovannoni G, Tomic D, Bright JR, Havrdova E (2017) “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179–1187CrossRefPubMedPubMedCentral
10.
Reeve K, On BI, Havla J, Burns J, Gosteli-Peter MA, Alabsawi A, Alayash Z, Gotschi A, Seibold H, Mansmann U, Held U (2023) Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Syst Rev 9(9):CD013606PubMed
11.
Gold R, Wolinsky JS, Amato MP, Comi G (2010) Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 3(6):351–367CrossRefPubMedPubMedCentral
12.
Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, Brescia Morra V, Pozzilli C, De Luca G, Inglese M, Salemi G, Maniscalco GT, Cocco E, Sola P, Lus G, Conte A, Amato MP, Granella F, Gasperini C, Bellantonio P, Totaro R, Rovaris M, Salvetti M, Torri Clerici VLA, Bergamaschi R, Maimone D, Scarpini E, Capobianco M, Comi G, Filippi M, Trojano M, Italian MSR (2021) Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 14:17562864211019574CrossRefPubMedPubMedCentral
13.
Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, Tomassini V, Wardle M, Pickersgill T, Robertson N, Tallantyre E (2019) Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76(5):536–541CrossRefPubMedPubMedCentral
14.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand’Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, M.S.S. Group (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175–187CrossRefPubMedPubMedCentral
15.
Bose G, Rush C, Atkins HL, Freedman MS (2021) A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Mult Scler Relat Disord 52:102945CrossRefPubMed
16.
Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, Duncan J, Millar S, Harty GT (2023) Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study. Mult Scler Relat Disord 76:104791CrossRefPubMed
17.
Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand’Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H, M.S.S. Group (2018) Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. Mult Scler 24(12):1617–1626CrossRefPubMed
18.
Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, Shaw C, Skibina O, Vucic S, Shuey N, Barnett MH, Parratt J, Butzkueven H, Jack D, Fabris J, Kalincik T (2021) Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Mult Scler 27(3):465–474CrossRefPubMed
19.
Negrotto L, Iut VC, Etchepare A, D’Eramo M, Grinspan A, Assefi A (2022) High persistence and low adverse events burden in cladribine treated MS patients from Argentina. Mult Scler Relat Disord 68:104403CrossRefPubMed
20.
Magalashvili D, Mandel M, Dreyer-Alster S, Didikin M, Harari G, Flechter S, Achiron A (2022) Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4. J Neuroimmunol 372:577966CrossRefPubMed
21.
Mohn N, Skripuletz T, Suhs KW, Menck S, Voss E, Stangel M (2019) Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. Ther Adv Neurol Disord 12:1756286419887596CrossRefPubMedPubMedCentral
22.
Petracca M, Ruggieri S, Barbuti E, Ianniello A, Fantozzi R, Maniscalco GT, Andreone V, Landi D, Marfia GA, Di Gregorio M, Iodice R, Sinisi L, Maida E, Missione R, Coppola C, Bonavita S, Borriello G, Centonze D, Lus G, Pozzilli C, Signoriello E (2022) Predictors of cladribine effectiveness and safety in multiple sclerosis: A real-world, multicenter, 2-year follow-up study. Neurol Ther 11(3):1193–1208CrossRefPubMedPubMedCentral
23.
Rauma I, Viitala M, Kuusisto H, Atula S, Sipila JOT, Ryytty M, Soilu-Hanninen M, Jarvinen E (2022) Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord 61:103755CrossRefPubMed
24.
Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schafer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M (2023) Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. Mult Scler Relat Disord 70:104491CrossRefPubMed
25.
Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H (2023) Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Mult Scler 29(2):221–235CrossRefPubMed
26.
Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M, M.S.S.G. oral cladribine for early (2014) Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol 13(3):257–67CrossRefPubMed
27.
Poser CM (1986) Pathogenesis of multiple sclerosis. A critical reappraisal. Acta Neuropathol (Berl) 71(1–2):1–10CrossRefPubMed
28.
Annovazzi FJP, Margoni M, Nozolillo A et al (2021) Two year relapse free and NEDA status with Cladribine in a real life population: a multicentre study. ECTRIMS 2021 congress. Mult Scler J 453
29.
Zanetta C, Sangalli F, Guerrieri S et al (2021) Efficacy/safety profile of cladribine in an italian real-life cohort of relapsing remitting multiple sclerosis patients. EAN 2021. Eur J Neurol Abstract (EPR-179) 325
30.
Zanetta C, Rocca MA, Meani A, Martinelli V, Ferre L, Moiola L, Filippi M (2023) Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol 270(7):3553–3564CrossRefPubMedPubMedCentral
31.
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, KubalaHavrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand’Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T, M.S.s. group (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307–316CrossRefPubMed
32.
Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, Kleinschnitz C, Havrdova EK, Magyari M, Selchen D, Vermersch P, Wiendl H, Van Wijmeersch B, Salloukh H, Yamout B (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. Mult Scler Relat Disord 69:104459CrossRefPubMed
33.
Annovazzi P, Prosperini L, Capuano R et al (2020) Relapse-free and neda status with cladribine in a real life population: a multicentre study. ECTRIMS congress. Mult Scler J 551
34.
Mustonen T, Rauma I, Hartikainen P, Kruger J, Niiranen M, Selander T, Simula S, Remes AM, Kuusisto H (2020) Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. Mult Scler Relat Disord 38:101498CrossRefPubMed
35.
Pfeuffer S, Rolfes L, Hackert J, Kleinschnitz K, Ruck T, Wiendl H, Klotz L, Kleinschnitz C, Meuth SG, Pul R (2022) Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler 28(2):257–268CrossRefPubMed
36.
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S (2019) Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 12:1756286419837809CrossRefPubMedPubMedCentral
37.
Nygaard GO, Torgauten H, Skattebol L, Hogestol EA, Sowa P, Myhr KM, Torkildsen O, Celius EG (2022) Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Mult Scler Relat Disord 62:103812CrossRefPubMed
38.
Meuth SG, Bayas A, Kallmann B, Kleinschnitz C, Linker R, Rieckmann P, Maurer M (2020) Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother 21(16):1965–1969CrossRefPubMed
Metadaten
Titel
Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness
verfasst von
Berenice A. Silva
Alejandra Heriz
Jeremías Ayerbe
Luciana Lázaro
Magdalena Casas
Pablo López
Verónica Tkachuk
María Eugenia Balbuena
Débora Nadur
Susana Liwacki
Geraldine Luetic
Marcos Burgos
Federico Casales
Agustina Piedrabuena
Edgar Carnero Contentti
Agustina Zárate
Gisela Zanga
Judith Steinberg
Carolina Mainella
Darío Tavolini
Javier Hryb
Felisa Leguizamón
Fátima Pagani Cassará
Gustavo José
Paula Carrizo
Pedro Nofal
Belén Luis
Cecilia Pita
Jimena Míguez
Ricardo Alonso
Publikationsdatum
11.09.2024
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 12/2024
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-024-07763-7

Weitere Artikel der Ausgabe 12/2024

Anti-Hu associated paraneoplastic upper and lower motor neuropathy triggered by atezolizumab

  • Letter to the Editor

Regression-based normative data for Corsi Span and Supraspan learning and recall among Italian adults

  • Open Access
  • Original Article

Clinical characteristics and therapeutic effect of myasthenia gravis coexisting with thyroid eye disease

  • Original Article

Acute cerebral infarction in a patient with Paget`s disease

  • Letter to the Editor

Effects of various exercise interventions on motor function in cerebral palsy patients: a systematic review and network meta-analysis

  • Original Article

Charcot-Marie-Tooth type 2CC misdiagnosed as Chronic Inflammatory Demyelinating Polyradiculoneuropathy

  • Brief Communication

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

„Wir wollen die Bedeutung von Gen- und Umwelteinflüssen besser verstehen“

Eine Mutation in einem einzelnen Gen kann bei Mäusen eine Art Bipolarstörung auslösen. PD Dr. Jan Deussing vom Max-Planck-Institut für Psychiatrie in München sieht in solchen Tiermodellen eine Möglichkeit, den Ursachen der Erkrankung auf den Grund zu gehen.

Suizidassistenz erhöht Suizidzahlen: Aktuelle Ergebnisse der geplanten S3-Leitlinie

Erstmals wird in Deutschland eine S3-Leitlinie zum Thema Suizidalität erarbeitet. Ziel ist es, die Versorgung in suizidalen Krisen durch einheitliche Standards zu verbessern. Erste Ergebnisse der bisherigen Leitlinienarbeit wurden auf dem DGPPN-Kongress vorgestellt.

Kaum Vorteile durch intraarterielle Lyse während Thrombektomie

Nach der Thrombektomie kleinere Fragmente über eine intraarterielle Lyse auflösen – dies könnte die Schlaganfalltherapie verbessern. Zwei aktuelle Studien ergeben für die periprozedurale Lyse jedoch keine großen Vorteile. Die Frage, wie viel sie nützt, bleibt weiter offen.

Nasenstimulation lindert chronische Migräne

Wird die Naseninnenseite durch Vibrationen stimuliert, kann dies offenbar die Zahl der Migränetage von Menschen mit chronischer Migräne deutlich senken. Darauf deuten die Resultate einer randomisiert-kontrollierten deutsch-finnischen Untersuchung.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise